Samumed's Osteoarthritis Research Selected for an Oral Presentation at a Gordon Research Conference
Samumed Successfully Completed 52-week Phase 2 Study for Treatment of Osteoarthritis of the Knee
Samumed Receives Orphan Drug Designation from FDA for SM04646 as a Treatment for Idiopathic Pulmonary Fibrosis (IPF)
The Wnt Pathway
Your browser does not support HTML5 video.
© Samumed, LLC. All rights reserved